SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001438533-22-000014
Filing Date
2022-04-04
Accepted
2022-04-04 17:29:26
Documents
5
Period of Report
2022-05-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A tvtx-2022definitiveproxy.htm DEF 14A 1286335
2 GRAPHIC image0a04a.jpg GRAPHIC 8335
3 GRAPHIC image2a02a.jpg GRAPHIC 10405
4 GRAPHIC image3a02a.jpg GRAPHIC 10716
5 GRAPHIC image4a02a.jpg GRAPHIC 10976
  Complete submission text file 0001438533-22-000014.txt   1322169
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36257 | Film No.: 22803940
SIC: 2834 Pharmaceutical Preparations